Molecular Diagnosis of Cancer

CHF 180.75
Auf Lager
SKU
2E4PNS9R1FO
Stock 1 Verfügbar
Geliefert zwischen Mo., 10.11.2025 und Di., 11.11.2025

Details

We are currently experiencing a fundamental shift in the way in which we approach the characterization of cancer. Never before has the make up of cancer tissues and individual cells been so exhaustively researched and char- terized. We are now capable of producing molecular fingerprints that ch- acterize the expression of all known and unknown genes within tumors and their surrounding tissues. More than 30,000 different genes may be measured in each patient's tumor in a single experiment. Simultaneously, novel therapies that exploit the molecular roadmap have been developed and are now being offered to patients. These novel agents, such as Glivec, Herceptin, Iressa, and others, specifically target individual genes within tumors and can produce d- matic responses in some patients. These drugs are only the forerunners of a coming tidal wave of novel therapeutics that individually target specific m- ecules within cancer cellsmore than 300 such agents are currently in phase I or II clinical trials. This is an exciting time for cancer specialists and patients alike. However, if we have learned anything from the past 50 or more years of research into cancer, it is that Lord Beaverbrook, in founding the British national health service in the 1950s, was frighteningly prescient when he defined the primary goal of health care to be Diagnosis, Diagnosis, Diag- sis. Now, more than ever, it is essential that appropriate diagnostic methods and approaches are applied to the selection of patients for treatment.

Includes supplementary material: sn.pub/extras

Klappentext
The growing tide of novel therapeutics that target molecules within a specific individual's cancer cells-over 300 such agents are currently in phase I or II clinical trials-makes it essential to employ appropriate diagnostic methods and approaches when selecting patients for treatment. In Molecular Diagnosis of Cancer: Methods and Protocols, a panel of leading international experts in molecular diagnostic medicine present a diverse collection of readily reproducible methods, derived from their own research for cancer detection. Highlights include FISH-based methodologies currently used in the diagnosis of solid tumors, the molecular diagnosis of genetic abnormalities by DNA array technologies-including sequence-specific oligonucleotide arrays and CGH arrays-and methodologies directed at the detection of epigenetic events and at quantitative gene expression. The authors apply these novel diagnostic procedures to a broad range of cases taken from cytology, solid tumor pathology, hematology, and rare cell detection, paying special attention to potential future developments and the practical problems of dealing with quality control and accuracy. The protocols presented follow the successful Methods in Molecular Medicine™ series format, each one offering step-by-step laboratory instructions, an introduction outlining the principle behind the technique, lists of equipment and reagents, and tips on troubleshooting and avoiding known pitfalls.
Cutting-edge and highly practical, Molecular Diagnosis of Cancer: Methods and Protocols offers pathologists providing molecular diagnostic services and researchers seeking molecularly targeted therapeutic approaches a broad array of today's most powerful methods and techniques.

Inhalt
Prognostic and Predictive Factors.- Assessment of Predictive Values of Tumor Markers.- Quality Assurance of Predictive Markers in Breast Cancer.- Extraction of Nucleic Acid Templates.- Microdissection and Extraction of DNA From Archival Tissue.- Fluorescence In Situ Hybridization.- HER2 FISH in Breast Cancer.- Fluorescence In Situ Hybridization for BCR-ABL.- UroVysion™ Multiprobe FISH in Urinary Cytology.- Chromogenic In Situ Hybridization in Tumor Pathology.- Comparative Genomic Hybridization and Fluorescence In Situ Hybridization in Chronic Lymphocytic Leukemia.- Molecular Characterization of Human Papillomaviruses by PCR and In Situ Hybridization.- A Nested RT-PCR Assay to Detect BCR/abl.- TP53 Mutation Detection by SSCP and Sequencing.- PCR Diagnosis of T-Cell Lymphoma in Paraffin-Embedded Bone Marrow Biopsies.- Circulating DNA Analysis.- Microsatellite Instability.- Diagnostic and Prognostic Significance of the Methylation Status of Myf-3 in Lymphoproliferative Disorders.- Quantitative Analysis of PRAME for Detection of Minimal Residual Disease in Leukemia.- Determination of Cyclin D1 Expression by Quantitative Real-Time, Reverse-Transcriptase Polymerase Chain Reaction.- Detection of Telomerase hTERT Gene Expression and Its Splice Variants by RT-PCR.- Detection of Telomerase Enzyme Activity by TRAP Assay.- Identification of TP53 Mutations in Human Cancers Using Oligonucleotide Microarrays.- Detection of K-ras Mutations by a Microelectronic DNA Chip.- Microarray-Based CGH in Cancer.- Tissue Microarrays.

Weitere Informationen

  • Allgemeine Informationen
    • Sprache Englisch
    • Editor John M. S. Bartlett, Joseph E. Roulston
    • Titel Molecular Diagnosis of Cancer
    • Veröffentlichung 10.11.2010
    • ISBN 1617373966
    • Format Kartonierter Einband
    • EAN 9781617373961
    • Jahr 2010
    • Größe H235mm x B155mm x T26mm
    • Untertitel Methods and Protocols
    • Gewicht 690g
    • Auflage Second Edition 2004
    • Genre Medizin
    • Lesemotiv Verstehen
    • Anzahl Seiten 408
    • Herausgeber Humana Press
    • GTIN 09781617373961

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.
Made with ♥ in Switzerland | ©2025 Avento by Gametime AG
Gametime AG | Hohlstrasse 216 | 8004 Zürich | Schweiz | UID: CHE-112.967.470